FDAs OTAT Agrees to Primary Endpoint for Back Pain
Filed with ASX · · 3 pages · English
Story so far
Earlier from Mesoblast
- Update on Novartis Agreement
- MSB and Oaktree Conclude Refinancing of Senior Debt Facility
- AHA Late-Breaker - Rexlemestrocel Improves Cardiac Outcomes
- MSB Annual Financial Results and Operational Progress
- Mesoblast Update on Chronic Low Back Pain Program
Later from Mesoblast
- Appendix 4C Quarterly Activity Report
- Ulcerative Colitis & Crohns Results Presented at ECCO
- Second Quarter Results Presentation
- S&P DJI Announces March 2022 Quarterly Rebalance
- MSB Q3 Financial Results and Operational Highlights
Follow Mesoblast into a list and get an email when it puts out news.
Follow Mesoblast